New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 7, 2014
03:19 EDTBSXBoston Scientific acquires IoGyn
Boston Scientific has signed a definitive agreement to acquire IoGyn, a pre-commercial stage company. The transaction is expected to close within days. IoGyn has developed and received U.S. Food and Drug Administration, FDA, clearance for the Symphion System, a next generation system for hysteroscopic intrauterine tissue removal including fibroids and polyps. This acquisition enables the pairing of the Symphion System with the Boston Scientific Genesys HTA System for abnormal uterine bleeding, to create a compelling set of gynecologic surgery products.Prior to the acquisition, Boston Scientific held approximately 28% equity ownership, in addition to notes receivable of approximately $8M. Total consideration included a net cash payment of approximately $65M at closing to acquire the remaining 72% of IoGyn and repay outstanding debt. Boston Scientific expects the transaction to have an immaterial impact on its adjusted earnings per share in 2014 and 2015, and to be accretive starting in 2016. On a GAAP earnings per share basis, Boston Scientific expects the transaction to be slightly accretive in 2014 as a result of a non-cash acquisition-related gain on its previously held equity investment, immaterial in 2015 and 2016, and to be less accretive than adjusted earnings per share thereafter as a result of acquisition-related net charges and amortization, which will be determined following the closing.
News For BSX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 1, 2015
16:17 EDTBSXNevro submits preliminary response to PTAB in patent case with Boston Scientific
Nevro (NVRO) announced that the company has submitted its preliminary response to the Patent Trial and Appeals Board, or PTAB, in response to two petitions for inter partes review, or IPR, filed by a unit of Boston Scientific (BSX), challenging the validity of certain claims in U.S. Patent No. 8,359,102, one of Nevro's 55 issued U.S. patents directed to Nevro's innovations in the neuromodulation field. The preliminary response is limited in scope by the rules governing the IPR process. The response is limited to setting forth the reasons why an IPR should not be instituted and cannot argue the merits or include any new testimonial evidence. By the rules governing the IPR process, the next step will be a decision by the PTAB to either institute or deny review of the petition. That determination is expected by December 1, Nevro said.
August 27, 2015
10:00 EDTBSXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:12 EDTBSXBoston Scientific upgraded to Buy on valuation at Goldman
Subscribe for More Information
August 24, 2015
16:32 EDTBSXBoston Scientific announces CE Mark for MRI labeling for ICD, CRT-D systems
Boston Scientific has received CE Mark on magnetic resonance imaging conditional labeling for the current family of EL and MINI implantable cardioverter defibrillator and the X4 cardiac resynchronization therapy defibrillator systems. This revised labeling ensures that future patients and those already implanted with these systems are able to undergo MRI scans if indicated.
August 19, 2015
16:48 EDTBSXBoston Scientific announces FDA approval of Innova Self-Expanding Stent System
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use